EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sethi, G.
Right arrow Articles by Aggarwal, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sethi, G.
Right arrow Articles by Aggarwal, B. B.
Experimental Biology and Medicine 233:21-31 (2008)
doi: 10.3181/0707-MR-196
© 2008 Society for Experimental Biology and Medicine


MINIREVIEW

Nuclear Factor-{kappa}B Activation: From Bench to Bedside

Gautam Sethi, Bokyung Sung and Bharat B. Aggarwal1

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 143, Houston, Texas 77030

To whom requests for reprints should be addressed at 1 Bharat B. Aggarwal, Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 143, Houston, TX 77030. Email: aggarwal{at}mdanderson.org

Nuclear factor-{kappa}B (NF-{kappa}B) is a proinflammatory transcription factor that has emerged as an important player in the development and progression of malignant cancers. NF-{kappa}B targets genes that promote tumor cell proliferation, survival, metastasis, inflammation, invasion, and angiogenesis. Constitutive or aberrant activation of NF-{kappa} is frequently encountered in many human tumors and is associated with a resistant phenotype and poor prognosis. The mechanism of such persistent NF-{kappa}B activation is not clear but may involve defects in signaling pathways, mutations, or chromosomal rearrangements. Suppression of constitutive NF-{kappa}B activation inhibits the oncogenic potential of transformed cells and thus makes NF-{kappa}B an interesting new therapeutic target in cancer.

Key Words: NF-{kappa}B • cancer • IKK • metastasis • invasion




This article has been cited by other articles:


Home page
Cancer Res.Home page
M. K. Kiessling, C. D. Klemke, M. M. Kaminski, I. E. Galani, P. H. Krammer, and K. Gulow
Inhibition of Constitutively Activated Nuclear Factor-{kappa}B Induces Reactive Oxygen Species- and Iron-Dependent Cell Death in Cutaneous T-Cell Lymphoma
Cancer Res., March 15, 2009; 69(6): 2365 - 2374.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. B. Harikumar, A. B. Kunnumakkara, K. S. Ahn, P. Anand, S. Krishnan, S. Guha, and B. B. Aggarwal
Modification of the cysteine residues in I{kappa}B{alpha} kinase and NF-{kappa}B (p65) by xanthohumol leads to suppression of NF-{kappa}B-regulated gene products and potentiation of apoptosis in leukemia cells
Blood, February 26, 2009; 113(9): 2003 - 2013.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Y. Kim and K. Ozato
The Sequestosome 1/p62 Attenuates Cytokine Gene Expression in Activated Macrophages by Inhibiting IFN Regulatory Factor 8 and TNF Receptor-Associated Factor 6/NF-{kappa}B Activity
J. Immunol., February 15, 2009; 182(4): 2131 - 2140.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. B. Aggarwal, R.V. Vijayalekshmi, and B. Sung
Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe
Clin. Cancer Res., January 15, 2009; 15(2): 425 - 430.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
B. T. Kawasaki, E. M. Hurt, T. Mistree, and W. L. Farrar
Targeting Cancer Stem Cells with Phytochemicals
Mol. Interv., August 1, 2008; 8(4): 174 - 184.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society for Experimental Biology and Medicine.